Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape

Immunological Investigations

Volumn 41, Issue 6-7, 2012, Pages 680-710

  Cohen, Peter A ^a   Ko, Jennifer S ^b   Storkus, Walter J ^c   Spencer, Christopher D ^a   Bradley, Judy M ^a   Gorman, Jessica E ^a   McCurry, Dustin B ^a   Zorro Manrique, Soroya ^a   Dominguez, Anna Lucia ^a   Pathangey, Latha B ^a   Rayman, Patricia A ^b   Rini, Brian I ^b   Gendler, Sandra J ^a   Finke, James H ^b  

^a MAYO CLINIC   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

G CSF; GM CSF; MDSC; Myeloid derived suppressor cells; STAT3; STAT5; Sunitinib

Indexed keywords

ARGINASE; ARGININE; CD11B ANTIGEN; CD15 ANTIGEN; GAMMA INTERFERON RECEPTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REACTIVE OXYGEN METABOLITE; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUNITINIB; TRANSCRIPTION FACTOR FOXP3;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL INTERACTION; CELL LINEAGE; DRUG MECHANISM; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH2 CELL; TUMOR IMMUNITY;

ANIMALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; INDOLES; MICE; MYELOID PROGENITOR CELLS; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN KINASE INHIBITORS; PYRROLES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84866905318     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.703745     Document Type: Article

References (95)

1. Almand, B., Clark, J. I., et al. (2001). Increased production of immaturemyeloid cells incancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166(1): 678-689.
2. Bingisser, R. M., Tilbrook, P. A., et al. (1998). Macrophage-derived nitric oxide regulatesT cell activation via reversible disruption of the Jak3/STAT5 signaling pathway.J. Immunol. 160(12): 5729-5734.
3. Bose, A., Taylor, J. L., et al. (2011). Sunitinib facilitates the activation and recruitment oftherapeutic anti-tumor immunity in concert with specific vaccination. Int J CancerBronte
4. V., Serafini, P., et al. (2003). IL-4-induced arginase 1 suppresses alloreactive Tcells in tumor-bearing mice. J. Immunol. 170(1): 270-278.
5. Brossart, P., Stuhler, G., et al. (1998). Her-2/neu-derived peptides are tumor-associatedantigens expressed by human renal cell and colon carcinoma lines and are recognizedby in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58(4): 732-736.
6. Brugarolas, J. (2007). Renal-cell carcinoma-molecular pathways and therapies. N. Engl.J. Med. 356(2): 185-187.
7. Brune, B., Gotz, C., et al. (1997). Superoxide formation and macrophage resistance tonitric oxide-mediated apoptosis. J. Biol. Chem. 272(11): 7253-7258.
8. Chklovskaia, E., Jansen, W., et al. (1999). Mechanism of flt3 ligand expression in bonemarrow failure: translocation fromintracellular stores to the surface of T lymphocytesafter chemotherapy-induced suppression of hematopoiesis. Blood 93(8): 2595-2604.
9. Cohen, P. A., Koski, G. K., et al. (2008). STAT3-and STAT5-dependent pathways competitivelyregulate the pan-differentiation of CD34pos cells into tumor-competentdendritic cells. Blood 112(5): 1832-1843.
10. Corzo, C. A., Cotter, M. J., et al. (2009). Mechanism regulating reactive oxygen species intumor-induced myeloid-derived suppressor cells. J. Immunol. 182(9): 5693-5701.
11. Dolcetti, L., Peranzoni, E., et al. (2010). Hierarchy of immunosuppressive strengthamong myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur.J. Immunol. 40(1): 22-35.
12. Dolganiuc, A., Paek, E., et al. (2008). Myeloid dendritic cells of patients with chronic HCVinfection induce proliferation of regulatory T lymphocytes. Gastroenterology 135(6): 2119-2127.
13. Duhe, R. J., Evans, G. A., et al. (1998). Nitric oxide and thiol redox regulation of Januskinase activity. Proc. Natl. Acad. Sci. USA 95(1): 126-131.
14. Eardley, D. D., Gershon, R. K. (1976). Induction of specific suppressor T cells in vitro.J. Immunol. 117(1): 313-318.
15. Esashi, E., Wang, Y. H., et al. (2008). The signal transducer STAT5 inhibits plasmacytoiddendritic cell development by suppressing transcription factor IRF8. Immunity 28(4): 509-520.
16. Fainaru, O., Hantisteanu, S., et al. (2011). Immature myeloid cells accumulate in mouseplacenta and promote angiogenesis. Am. J. Obstet. Gynecol. 204(6): 544 e18-23.
17. Filipazzi, P., Valenti, R., et al. (2007). Identification of a new subset of myeloid suppressorcells in peripheral blood of melanoma patients with modulation by agranulocyte-macrophage colony-stimulation factor-based antitumor vaccine.J. Clin. Oncol. 25(18): 2546-2553.
18. Finke, J., Ferrone, S., et al. (1999). Where have all the T cells gone? Mechanisms ofimmune evasion by tumors. Immunol. Today 20(4): 158-160.
19. Finke, J. H., Rayman, P., et al. (1990). Characterization of the cytolytic activity of CD4 + and CD8 + tumor-infiltrating lymphocytes in human renal cell carcinoma. CancerRes. 50(8): 2363-2370.
20. Finke, J. H., B. Rini, et al. (2008). Sunitinib reverses type-1 immune suppressionand decreases T-regulatory cells in renal cell carcinoma patients. Clin. CancerRes. 14(20): 6674-6682.
21. Gabrilovich, D. I., S. Nagaraj (2009). Myeloid-derived suppressor cells as regulators of theimmune system. Nat. Rev. Immunol. 9(3): 162-174.
22. Garcia, J. A. Rini, B. A. (2007). Recent progress in the management of advanced renal cellcarcinoma. CA Cancer J. Clin. 57(2): 112-125.
23. Gershon, R. K., Eardley, D. D., et al. (1976). Functional inactivation of suppressor T cellsby heat-killed macrophages. Nature 262(5565): 216-217.
24. Ghiringhelli, F., Puig, P. E., et al. (2005). Tumor cells convert immature myeloid dendriticcells into TGF-beta-secreting cells inducing CD4 +CD25 + regulatory T cell proliferation.J. Exp. Med. 202(7): 919-929.
25. Heng, D. Y., Bukowski, R. M. (2008). Anti-angiogenic targets in the treatment ofadvanced renal cell carcinoma. Curr Cancer Drug Targets 8(8): 676-62.
26. Heng, D. Y., Chi, K. N., et al. (2009). A population-based study evaluating the impact ofsunitinib on overall survival in the treatment of patients with metastatic renal cellcancer. Cancer 115(4): 776-783.
27. Hesse, M., Modolell, M., et al. (2001). Differential regulation of nitric oxide synthase-2and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shapedby the pattern of L-arginine metabolism. J. Immunol. 167(11): 6533-6544.
28. Hipp, M. M., Hilf, N., et al. (2008). Sorafenib, but not sunitinib, affects function ofdendritic cells and induction of primary immune responses. Blood 111(12): 5610-5620.
29. Hoechst, B., Ormandy, L. A., et al. (2008). A new population of myeloid-derived suppressorcells in hepatocellular carcinoma patients induces CD4( +)CD25( +)Foxp3( +) Tcells. Gastroenterology 135(1): 234-243.
30. Hu, S. K., Eardley, D. D., et al. (1983). Definition of two pathways for generation ofsuppressor T-cell activity. Proc. Natl. Acad. Sci. USA 80(12): 3779-3781.
31. Huang, B., Pan, P. Y., et al. (2006). Gr-1 +CD115 + immature myeloid suppressor cellsmediate the development of tumor-induced T regulatory cells and T-cell anergy intumor-bearing host. Cancer Res. 66(2): 1123-1131.
32. Jemal, A., Siegel, R., et al. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57(1): 43-66.
33. Kaelin, W. G., Jr. (2007). The von Hippel-Lindau tumor suppressor protein and clear cellrenal carcinoma. Clin. Cancer Res. 13(2 Pt 2): 680s-684s.
34. Kerbel, R. S. (2005). Therapeutic implications of intrinsic or induced angiogenic growthfactor redundancy in tumors revealed. Cancer Cell 8(4): 269-271.
35. Klapper, J. A., Downey, S. G., et al. (2008). High-dose interleukin-2 for the treatment ofmetastatic renal cell carcinoma: a retrospective analysis of response and survival inpatients treated in the surgery branch at the National Cancer Institute between1986 and 2006. Cancer 113(2): 293-301.
36. Kmieciak, M., Gowda, M., et al. (2009). Human T cells express CD25 and Foxp3 uponactivation and exhibit effector/memory phenotypes without any regulatory/suppressorfunction. J. Transl. Med. 7: 89.
37. Ko, J. S., Rayman, P., et al. (2010). Direct and differential suppression of myeloid-derivedsuppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70(9): 3526-3536.
38. Ko, J. S., Zea, A. H., et al. (2009). Sunitinib mediates reversal of myeloid-derivedsuppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res.15(6): 2148-2157.
39. Korn, T., Oukka, M. (2007). Dynamics of antigen-specific regulatory T-cells in the contextof autoimmunity. Semin. Immunol. 19(4): 272-278.
40. Kusmartsev, S., Eruslanov, E., et al. (2008). Oxidative stress regulates expression ofVEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cellcarcinoma. J. Immunol. 181(1): 346-353.
41. Lee, J. M., Seo, J. H., et al. (2011). The restoration of myeloid-derived suppressor cells asfunctional antigen-presenting cells by NKT cell help and all-trans-retinoic acidtreatment. Int. J. Cancer
42. Linehan, W. M., Zbar, B. (2004). Focus on kidney cancer. Cancer Cell 6(3): 223-228.
43. MacDonald, K. P., Rowe, V., et al. (2005). Cytokine expanded myeloid precursors functionas regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 174(4): 1841-1850.
44. Mahdipour, E., Charnock, J. C., et al. (2011). Hoxa3 promotes the differentiation ofhematopoietic progenitor cells into proangiogenic Gr-1 +CD11b + myeloid cells.Blood 117(3): 815-826.
45. Marigo, I., Dolcetti, L., et al. (2008). Tumor-induced tolerance and immune suppressionby myeloid derived suppressor cells. Immunol Rev. 222: 162-179.
46. Miller, K. D., Sweeney, C. J., et al. (2005). Can tumor angiogenesis be inhibited withoutresistance? Experientia. (94): 95-112.
47. Mirza, N., Fishman, M. et al. (2006). All-trans-retinoic acid improves differentiation ofmyeloid cells and immune response in cancer patients. Cancer Res. 66(18): 9299-9307.
48. Motzer, R. J., Hutson, T. E., et al. (2007). Sunitinib versus interferon alfa in metastaticrenal-cell carcinoma. N. Engl. J. Med. 356(2): 115-124.
49. Motzer, R. J., Michaelson, M. D., et al. (2006). Activity of SU11248, a multitargetedinhibitor of vascular endothelial growth factor receptor and platelet-derived growthfactor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1): 16-24.
50. Movahedi, K., Guilliams, M., et al. (2008). Identification of discrete tumor-inducedmyeloid-derived suppressor cell subpopulations with distinct T cell-suppressiveactivity. Blood 111(8): 4233-4244.
51. Muranski, P., Boni, A., et al. (2008). Tumor-specific Th17-polarized cells eradicate largeestablished melanoma. Blood 112(2): 362-373.
52. Nagaraj, S., Nelson, A., et al. (2012). Antigen-specific CD4( +) T cells regulate function ofmyeloid-derived suppressor cells in cancer via retrograde MHC class II signaling.Cancer Res. 72(4): 928-938.
53. Nayak, S., Cao, O., et al. (2009). Prophylactic immune tolerance induced by changingthe ratio of antigen-specific effector to regulatory T cells. J. Thromb. Haemost. 7(9): 1523-1532.
54. Nelson, E. A., Walker, S. R., et al. (2011). The STAT5 inhibitor pimozide decreasessurvival of chronic myelogenous leukemia cells resistant to kinase inhibitors.Blood 117(12): 3421-3429.
55. Neumann, E., Engelsberg, A., et al. (1998). Heterogeneous expression of the tumorassociatedantigens RAGE-1, PRAME, and glycoprotein 75 in human renal cellcarcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58(18): 4090-4095.
56. Ochoa, A. C., Zea, A. H., et al. (2007). Arginase, prostaglandins, and myeloid-derivedsuppressor cells in renal cell carcinoma. Clin. Cancer Res. 13(2 Pt 2): 721s-726s.
57. Onishi, T., Ohishi,Y., et al. (1999). Anassessment of the immunological environment basedon intratumoral cytokine production in renal cell carcinoma. BJUInternational. 83(4): 488-492.
58. Ostrand-Rosenberg, S., Clements, V. K., et al. (2002). Resistance to metastatic disease inSTAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFNgammadependent. J. Immunol. 169(10): 5796-5804.
59. Ozao-Choy, J., Ma, G., et al. (2009). The novel role of tyrosine kinase inhibitor in thereversal of immune suppression and modulation of tumor microenvironment forimmune-based cancer therapies. Cancer Res. 69(6): 2514-2522.
60. Page, B. D., Khoury, H., et al. (2012). Small molecule STAT5-SH2 domain inhibitorsexhibit potent antileukemia activity. J. Med. Chem. 55(3): 1047-1055.
61. Pan, P. Y., Ma, G., et al. (2010). Immune stimulatory receptor CD40 is required for T-cellsuppression and T regulatory cell activation mediated by myeloid-derived suppressorcells in cancer. Cancer Res. 70(1): 99-108.
62. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy.Nat. Rev. Cancer 12(4): 252-264.
63. Pardoll, D. M., Topalian, S. L. (1998). The role of CD4 + T cell responses in antitumorimmunity. Curr. Opin. Immunol. 10(5): 588-594.
64. Powell, D. J., Jr., Parker, L. L., et al. (2005). Large-scale depletion of CD25 + regulatory Tcells from patient leukapheresis samples. J. Immunother. 28(4): 403-411.
65. Puisieux, I., Bain, C., et al. (1996). Restriction of the T-cell repertoire in tumorinfiltratinglymphocytes from nine patients with renal-cell carcinoma. Relevance ofthe CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int.J. Cancer 66(2): 201-208.
66. Rodriguez, P. C., Ernstoff, M. S., et al. (2009). Arginase I-producing myeloid-derivedsuppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.Cancer Res. 69(4): 1553-1560.
67. Rodriguez, P. C., Hernandez, C. P., et al. (2005). Arginase I in myeloid suppressor cells isinduced by COX-2 in lung carcinoma. J. Exp. Med. 202(7): 931-939.
68. Rodriguez, P. C., Quiceno, D. G., et al. (2007). L-arginine availability regulates Tlymphocytecell-cycle progression. Blood 109(4): 1568-1573.
69. Rodriguez, P. C., Quiceno, D. G., et al. (2004). Arginase I production in the tumormicroenvironment by mature myeloid cells inhibits T-cell receptor expression andantigen-specific T-cell responses. Cancer Res. 64(16): 5839-5849.
70. Rodriguez, P. C., Zea, A. H., et al. (2003). L-arginine consumption by macrophagesmodulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171(3): 1232-1239.
71. Roskoski, R., Jr. (2007). Sunitinib: a VEGF and PDGF receptor protein kinase andangiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356(2): 323-328.
72. Schendel, D. J., Gansbacher, B., et al. (1993). Tumor-specific lysis of human renal cellcarcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition ofautologous and allogeneic tumor lines. J. Immunol. 151(8): 4209-4220.
73. Schmielau, J., Finn, O. J. (2001). Activated granulocytes and granulocyte-derived hydrogenperoxide are the underlying mechanism of suppression of t-cell function inadvanced cancer patients. Cancer Res. 61(12): 4756-4760.
74. Schwartz, A., Gershon, R. K. (1984). Regulation of in vitro cytotoxic T lymphocyte generation.III. Interactions or regulatory T cell subsets in suppressor and targetpopulations. J. Mol. Cell Immunol. 1(4): 237-252.
75. Serafini, P., Carbley, R., et al. (2004). High-dose granulocyte- macrophage colonystimulatingfactor-producing vaccines impair the immune response through therecruitment of myeloid suppressor cells. Cancer Res. 64(17): 6337-6343.
76. Serafini, P., Mgebroff, S., et al. (2008). Myeloid-derived suppressor cells promote crosstolerancein B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68(13): 5439-5449.
77. Sinha, P., Clements, V. K., et al. (2007). Cross-talk between myeloid-derived suppressorcells and macrophages subverts tumor immunity toward a type 2 response.J. Immunol. 179(2): 977-983.
78. Sinha, P., Clements, V. K., et al. (2005). Reduction of myeloid-derived suppressor cellsand induction of M1 macrophages facilitate the rejection of established metastaticdisease. J. Immunol. 174(2): 636-645.
79. Smith, F. O., Downey, S. G., et al. (2008). Treatment of metastatic melanoma usinginterleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14(17): 5610-5618.
80. Solito, S., Bronte, V., et al. (2011). Antigen specificity of immune suppression by myeloidderivedsuppressor cells. J. Leukoc. Biol. 90(1): 31-36.
81. Steffens, M. G., J. C. Oosterwijk-Wakka, et al. (1999). Immunohistochemical analysis oftumor antigen saturation following injection of monoclonal antibody G250.Anticancer Res. 19(2A): 1197-1200.
82. Takaba, J., Mishima, V., et al. Role of bone marrow-derived monocytes/macrophages inthe repair of mucosal damage caused by irradiation and/or anticancer drugs in colitismodel. Mediators Inflamm. 2010: 634145.
83. Talmadge, J. E. (2007). Pathways mediating the expansion and immunosuppressiveactivity of myeloid-derived suppressor cells and their relevance to cancer therapy.Clin. Cancer Res. 13(18 Pt 1): 5243-5248.
84. Tatsumi, T., Herrem, C. J., et al. (2003). Disease stage variation in CD4 + and CD8 + Tcellreactivity to the receptor tyrosine kinase EphA2 in patients with renal cellcarcinoma. Cancer Res. 63(15): 4481-4489.
85. Tatsumi, T., Kierstead, L. S., et al. (2002). Disease-associated bias in T helper type 1(Th1)/Th2 CD4( +) T cell responses against MAGE-6 in HLA-DRB10401( +) patientswith renal cell carcinoma or melanoma. J. Exp. Med. 196(5): 619-628.
86. Toes, R. E., Ossendorp, F., et al. (1999). CD4 T cells and their role in antitumor immuneresponses. J Exp. Med. 189(5): 753-756.
87. Troy, A. J., Summers, K. L., et al. (1998). Minimal recruitment and activation of dendriticcells within renal cell carcinoma. Clin Cancer Res 4(3): 585-593.
88. Uzzo, R. G., Rayman, P., et al. (1999). Mechanisms of apoptosis in T cells from patientswith renal cell carcinoma. Clin. Cancer Res. 5(5): 1219-1229.
89. Wang, Z., Davies, J. D. (2007). CD8 blockade promotes the expansion of antigen-specificCD4 + FOXP3 + regulatory T cells in vivo. Int. Immunopharmacol. 7(2): 249-265.
90. Watanabe, S., Deguchi, K., et al. (2008). Tumor-induced CD11b +Gr-1 + myeloid cellssuppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181(5): 3291-3300.
91. Xin, H., Zhang, C., et al. (2009). Sunitinib inhibition of Stat3 induces renal cell carcinomatumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69(6): 2506-2513.
92. Yao, Q., Nishiuchi, R., et al. (2005). Human leukemias with mutated FLT3 kinase aresynergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5signal transduction pathway. Leukemia 19(9): 1605-1612.
93. Youn, J. I., Nagaraj, S., et al. (2008). Subsets of myeloid-derived suppressor cells intumor-bearing mice. J. Immunol. 181(8): 5791-5802.
94. Zea, A.H., Rodriguez, P. C., et al. (2005). Arginase-producing myeloid suppressor cellsin renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65(8): 3044-3048.
95. Zhang, B., Jia, H., et al. (2010). Depletion of regulatory T cells facilitates growth ofestablished tumors: a mechanism involving the regulation of myeloid-derived suppressorcells by lipoxin A4. J. Immunol. 185(12): 7199-7206.